These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 37848636)

  • 21. Cost-effectiveness analysis of dupilumab among patients with oral corticosteroid-dependent uncontrolled severe asthma in Japan.
    Tohda Y; Matsumoto H; Miyata M; Taguchi Y; Ueyama M; Joulain F; Arakawa I
    J Asthma; 2022 Nov; 59(11):2162-2173. PubMed ID: 34752208
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biologics in severe asthma.
    Pelaia C; Pelaia G; Crimi C; Longhini F; Lombardo N; Savino R; Sciacqua A; Vatrella A
    Minerva Med; 2022 Feb; 113(1):51-62. PubMed ID: 33555158
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anaphylaxis to three humanized antibodies for severe asthma: a case study.
    Jingo K; Harada N; Nishioki T; Torasawa M; Yamada T; Asao T; Takagi H; Takeshige T; Ito J; Takahashi K
    Allergy Asthma Clin Immunol; 2020; 16():46. PubMed ID: 32536947
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biologics for chronic rhinosinusitis.
    Chong LY; Piromchai P; Sharp S; Snidvongs K; Philpott C; Hopkins C; Burton MJ
    Cochrane Database Syst Rev; 2020 Feb; 2(2):CD013513. PubMed ID: 32102112
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biologics for oral corticosteroid-dependent asthma.
    Yılmaz İ
    Allergy Asthma Proc; 2020 May; 41(3):151-157. PubMed ID: 32375958
    [No Abstract]   [Full Text] [Related]  

  • 26. [Adverse events in biologics for severe asthma].
    Dargentolle G; Georges M; Beltramo G; Poisson C; Bonniaud P
    Rev Mal Respir; 2024 May; 41(5):372-381. PubMed ID: 38653607
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Omalizumab-associated anaphylactic reactions reported between January 2007 and June 2008.
    Lin RY; Rodriguez-Baez G; Bhargave GA
    Ann Allergy Asthma Immunol; 2009 Nov; 103(5):442-5. PubMed ID: 19927545
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma.
    Katsaounou P; Buhl R; Brusselle G; Pfister P; Martínez R; Wahn U; Bousquet J
    Respir Med; 2019 Apr; 150():51-62. PubMed ID: 30961951
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improvement in Olfaction in Patients With CRSwNP and Severe Asthma Taking Anti-IgE and Anti-IL-5 Biologics: A Real-Life Study.
    Barroso B; Valverde-Monge M; Alobid I; Olaguibel JM; Rial MJ; Quirce S; Arismendi E; Barranco P; Betancor D; Bobolea I; Cárdaba B; Cruz Carmona MJ; Curto E; Domínguez-Ortega J; González-Barcala FJ; Martínez-Rivera C; Mahíllo-Fernández I; Muñoz X; Picado C; Plaza V; Rodrigo Muñoz JM; Soto-Retes L; Valero A; Del Pozo V; Mullol J; Sastre J
    J Investig Allergol Clin Immunol; 2023 Feb; 33(1):37-44. PubMed ID: 35416154
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incidence of Anti-Drug Antibodies to Monoclonal Antibodies in Asthma: A Systematic Review and Meta-Analysis.
    Chen ML; Nopsopon T; Akenroye A
    J Allergy Clin Immunol Pract; 2023 May; 11(5):1475-1484.e20. PubMed ID: 36716995
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular Targets for Biological Therapies of Severe Asthma.
    Pelaia C; Crimi C; Vatrella A; Tinello C; Terracciano R; Pelaia G
    Front Immunol; 2020; 11():603312. PubMed ID: 33329598
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biologic treatment eligibility for real-world patients with severe asthma: The IDEAL study.
    Albers FC; Müllerová H; Gunsoy NB; Shin JY; Nelsen LM; Bradford ES; Cockle SM; Suruki RY
    J Asthma; 2018 Feb; 55(2):152-160. PubMed ID: 28622052
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative Efficacy of Anti IL-4, IL-5 and IL-13 Drugs for Treatment of Eosinophilic Asthma: A Network Meta-analysis.
    Iftikhar IH; Schimmel M; Bender W; Swenson C; Amrol D
    Lung; 2018 Oct; 196(5):517-530. PubMed ID: 30167841
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anaphylaxis Associated With Allergen Specific Immunotherapy, Omalizumab, and Dupilumab: A Real World Study Based on the US Food and Drug Administration Adverse Event Reporting System.
    Bian S; Zhang P; Li L; Wang Z; Cui L; Xu Y; Guan K; Zhao B; Chen Z
    Front Pharmacol; 2021; 12():767999. PubMed ID: 34744748
    [No Abstract]   [Full Text] [Related]  

  • 35. [Biologics for the treatment of severe asthma: Current status report 2023].
    Paçacı Çetin G; Kepil Özdemir S; Can Bostan Ö; Öztop N; Çelebi Sözener Z; Karakaya G; Gelincik Akkor A; Yılmaz İ; Mungan D; Bavbek S
    Tuberk Toraks; 2023 Jun; 71(2):176-187. PubMed ID: 37345400
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Global Variability in Administrative Approval Prescription Criteria for Biologic Therapy in Severe Asthma.
    Porsbjerg CM; Menzies-Gow AN; Tran TN; Murray RB; Unni B; Audrey Ang SL; Alacqua M; Al-Ahmad M; Al-Lehebi R; Altraja A; Belevskiy AS; Björnsdóttir US; Bourdin A; Busby J; Canonica GW; Christoff GC; Cosio BG; Costello RW; FitzGerald JM; Fonseca JA; Hansen S; Heaney LG; Heffler E; Hew M; Iwanaga T; Jackson DJ; Kocks JWH; Kallieri M; Bruce Ko HK; Koh MS; Larenas-Linnemann D; Lehtimäki LA; Loukides S; Lugogo N; Maspero J; Papaioannou AI; Perez-de-Llano L; Pitrez PM; Popov TA; Rasmussen LM; Rhee CK; Sadatsafavi M; Schmid J; Siddiqui S; Taillé C; Taube C; Torres-Duque CA; Ulrik C; Upham JW; Wang E; Wechsler ME; Bulathsinhala L; Carter V; Chaudhry I; Eleangovan N; Hosseini N; Rowlands MA; Price DB; van Boven JFM
    J Allergy Clin Immunol Pract; 2022 May; 10(5):1202-1216.e23. PubMed ID: 34990866
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of Monoclonal Antibodies for Treatment of Uncontrolled Eosinophilic Asthma.
    Koski RR; Grzegorczyk KM
    J Pharm Pract; 2020 Aug; 33(4):513-522. PubMed ID: 31046541
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anaphylactic reactions associated with omalizumab administration: Analysis of a case-control study.
    Lieberman PL; Umetsu DT; Carrigan GJ; Rahmaoui A
    J Allergy Clin Immunol; 2016 Sep; 138(3):913-915.e2. PubMed ID: 27236498
    [No Abstract]   [Full Text] [Related]  

  • 39. Parasitic infections related to anti-type 2 immunity monoclonal antibodies: a disproportionality analysis in the food and drug administration's adverse event reporting system (FAERS).
    Pera V; Brusselle GG; Riemann S; Kors JA; Van Mulligen EM; Parry R; de Wilde M; Rijnbeek PR; Verhamme KMC
    Front Pharmacol; 2023; 14():1276340. PubMed ID: 38035014
    [No Abstract]   [Full Text] [Related]  

  • 40. Lower Use of Biologics for the Treatment of Asthma in Publicly Insured Individuals.
    Akenroye AT; Heyward J; Keet C; Alexander GC
    J Allergy Clin Immunol Pract; 2021 Nov; 9(11):3969-3976. PubMed ID: 33556592
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.